Prostate Cancer Clinical Trials

289 studies are recruiting for prostate cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

   AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be re…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC/Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   7 in total

   Run by

   Angiex, Inc.

   See if you can join NCT06440005 on ClinicalTrials.gov

2. Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

   This is a single-arm, open-label phase 2 study to evaluate the role of pacritinib for patients with metastatic castrate-resistant prostate cancer that have progressed on ARSI. Patients will receive pacritinib 200 mg twice daily. To be eligible, patients must have a biopsy of a metastatic site withi…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin

   Run by

   Medical College of Wisconsin

   See if you can join NCT07226713 on ClinicalTrials.gov

3. Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer

   Background: Prostate cancer is one of the most common cancers for men in the U.S. There are some new ways to take pictures of the cancer. There are also new ways to use image-guided biopsy and therapy. These could help manage prostate cancer. Researchers want to study how imaging can provide a prof…

   Stage

   Not phased

   Ages

   18 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03354416 on ClinicalTrials.gov

4. Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

   The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence

   Stage

   Phase 4

   Ages

   18 and older

   Site

   Oregon Health & Science University, Portland, Oregon

   Locations

   6 in total

   Run by

   Blue Earth Diagnostics

   See if you can join NCT07569926 on ClinicalTrials.gov

5. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

6. Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

   Background: Prostate cancer may return after treatment in 30,000 to 50,000 people each year. There is no clear best way to treat these people. Better treatments are needed. Objective: To test a study drug (enzalutamide), both alone and combined with a second drug (PDS01ADC), in people with prostate…

   Stage

   Phase 2

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06096870 on ClinicalTrials.gov

7. Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients

   The goal of this clinical trial is to test the utility of patient navigation by comparing high intensity patient navigation to low intensity navigation approaches to improving cancer trial enrollment of patients treated in academic and community cancer centers. Patient navigation is a strategy for …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

   Locations

   2 in total

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06138067 on ClinicalTrials.gov

8. A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

   Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Clearview Cancer Institute, Huntsville, Alabama

   Locations

   54 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT07005154 on ClinicalTrials.gov

9. Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

   This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UC San Diego Moores Cancer Center, La Jolla, California

   Locations

   6 in total

   Run by

   Janux Therapeutics

   See if you can join NCT07545811 on ClinicalTrials.gov

10. Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

    For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes. Specifically, patients enrolled in this study will undergo one of several d…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    NYU Langone Health, New York, New York

    Run by

    NYU Langone Health

    See if you can join NCT07801664 on ClinicalTrials.gov

11. Serial MRI Scans During Radiation Therapy

    This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulv…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Brigham and Women Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04188535 on ClinicalTrials.gov

12. A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

    This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621. The study is split into different modules which will look at AZD6621 delivered by different methods. The study is also further sp…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Orlando, Florida

    Locations

    26 in total

    Run by

    AstraZeneca

    See if you can join NCT07192614 on ClinicalTrials.gov

13. Collection of Blood From Patients With Cancer

    This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have abou…

    Stage

    Not phased

    Ages

    18 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT00034216 on ClinicalTrials.gov

14. PET/CT Characterization of Treatment Resistance

    This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that assessment. Participants in this study have advanced prostate cancer and are e…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Wisconsin, Madison, Wisconsin

    Run by

    University of Wisconsin, Madison

    See if you can join NCT05647564 on ClinicalTrials.gov

15. MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

    Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this r…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

    Locations

    2 in total

    Run by

    University of Chicago

    See if you can join NCT05710380 on ClinicalTrials.gov

16. Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis

    Background: - Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: - To o…

    Stage

    Not phased

    Ages

    3 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT01441089 on ClinicalTrials.gov

17. A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

    Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk pros…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago Comprehensive Cancer Center, Chicago, Illinois

    Locations

    4 in total

    Run by

    University of Chicago

    See if you can join NCT05726292 on ClinicalTrials.gov

18. Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

    This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended Phase II dose (RP2D) and assess the efficacy of INM176 in s…

    Stage

    Phase 1

    Ages

    40 and older

    Site

    Penn State Cancer Institute, Hershey, Pennsylvania

    Run by

    Milton S. Hershey Medical Center

    See if you can join NCT06600698 on ClinicalTrials.gov

19. Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

    There is evidence that Actinium-225 Prostate-Specific Membrane Antigen (225Ac-PSMA) has a potentially higher level of efficacy than 177 Lutetium Prostate-Specific Membrane Antigen (177Lu-PSMA) as a radioligand therapy. This single center, pilot study will compare differences in the mechanisms of ac…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    Thomas Hope

    See if you can join NCT07054346 on ClinicalTrials.gov

20. A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

    This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is looking at: * What side effects BPX-601 might cause * What …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    John Theurer Cancer Center, Hackensack, New Jersey

    Locations

    2 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT07543055 on ClinicalTrials.gov

21. Researching the Effect of Exercise on Cancer

    Researchers think that exercise may be able to prevent cancer from coming back by lowering ctDNA levels. The purpose of this study is to explore how aerobic exercise (exercise that stimulates and strengthens the heart and lungs and improves the body's use of oxygen) can reduce the level of ctDNA fo…

    Stage

    Not phased

    Ages

    18 and older

    Site

    City of Hope Medical Center, Durate, California

    Locations

    9 in total

    Run by

    City of Hope Medical Center

    See if you can join NCT04589468 on ClinicalTrials.gov

22. Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

    Background: Active surveillance (AS) is a standard approach to treat low and intermediate risk prostate cancer. For AS, disease progression is monitored. AS uses biopsies, prostate specific antigen (PSA) blood tests, and other tools. Researchers want to see if multiparametric magnetic resonance ima…

    Stage

    Not phased

    Ages

    18 and older

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Cancer Institute (NCI)

    See if you can join NCT04692675 on ClinicalTrials.gov

23. UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning

    The purpose of this study is to evaluate the use of ionizing-radiation photo acoustic imaging (iRAI) for proton radiation treatment.

    Stage

    Not phased

    Ages

    18 to 100

    Site

    Univeristy of Florida Health Proton Therapy Institute, Jacksonville, Florida

    Run by

    University of Florida

    See if you can join NCT06465966 on ClinicalTrials.gov

24. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Southern California, Los Angeles, California

    Locations

    10 in total

    Run by

    Nammi Therapeutics Inc

    See if you can join NCT06582017 on ClinicalTrials.gov

25. Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

    The purpose of this study is to determine whether [225Ac]Ac-PSMA-617 (AAA817), given for up to 6 cycles at a dose of 10 Megabecquerel (MBq) +/- 10%, plus androgen receptor pathway inhibitor (ARPI), improves the radiographic progression free survival (rPFS) compared to investigator's choice of stand…

    Stage

    Phase 3

    Ages

    18 to 100

    Site

    Urology Centers Of Alabama Pc, Homewood, Alabama

    Locations

    95 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT06855277 on ClinicalTrials.gov